Decision to add Merck oncology co-author to address JHO credibility gap
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T09:06:37.968Z Metadata:{"project":"oncology-fih-research/oncology-fih-research","type":"decision","obs_id":65495}
obs/65495 · decision · 2026-05-04T09:06:37.968Z
Decision to add Merck oncology co-author to address JHO credibility gap
The user is researching adding Dr. Jianda Yuan from Merck as a co-author to the JHO manuscript submission. This decision directly responds to the Claude Opus 4.7 peer review which identified the single-author urologic oncologist profile as a desk-reject signal for IF~40 hematology/oncology journals. Dr. Yuan’s profile from the extracted CV shows extensive relevant credentials: Senior Clinical Director at Merck Research Laboratory leading Head & Neck Late Oncology Product Development Team, 25+ years cancer immunotherapy research/clinical experience, pioneer in immune checkpoint blockade translational biomarker research, and global clinical trial experience across early/late oncology including KEYNOTE studies, ADCs, bispecific antibodies, and PD-1/VEGF programs. These credentials align precisely with the manuscript’s focus on early-phase oncology landscape analysis enriched for FIH programs, checkpoint inhibitors, ADCs, and bispecific antibodies. Adding this co-author would transform the manuscript from a single urologist-authored registry analysis into a collaboration with operational phase I oncology expertise from a major pharmaceutical company, potentially shifting the Claude Opus 4.7 assessment from 41/100 (reject with resubmission) toward the major-revision threshold by addressing the authorship/track-record penalty and adding industry-insider credibility to sponsor-transition and modality-evolution findings.
Concepts: [“why-it-exists”,“problem-solution”,“trade-off”]
Facts: [“User extracted contact information from Dr. Jianda Yuan CV: Senior Clinical Director at Merck Head & Neck Late Oncology PDT, email jiandayuanusa@gmail.com”,“Dr. Yuan has 25+ years oncology surgeon/tumor immunologist experience, Merck translational oncology expertise, and global clinical trial leadership in checkpoint inhibitors, ADCs, bispecifics”,“Current manuscript draft-v3-jho.md has placeholder “Email: to be provided before submission” for corresponding author”,“Claude Opus 4.7 review identified single-author credibility gap as fatal concern #2 for IF~40 journal submission”,“Adding Merck oncology co-author directly addresses reviewer recommendation #3: “Bring in a hem-onc co-author with phase I credentials""]
[← 回 Alfred Brain Hub]